© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Janux Therapeutics, Inc. (JANX) shows an Average True Range (ATR) of 1.16 and an Enterprise Value of 2.5B. Its average trading volume over the past 3 months is 1.73M, indicating liquidity. These fundamental metrics provide insight into JANX's underlying financial health and market activity.
Janux Therapeutics, Inc. (JANX) technical indicators as of January 1, 2026: the SMA 20 is -7.62%, SMA 50 at -40.05%, and SMA 200 at -44.78%. The RSI 14 value is 27.57, suggesting its current momentum. These technical analysis signals help assess JANX's price trends and potential future movements.
Janux Therapeutics, Inc. (JANX) stock performance overview as of January 1, 2026: The 52-week high is $61.59 (currently -77.59% below), and the 52-week low is $13.62 (currently 0.29% above). Over the past year, JANX's performance is -75.42%, compared to the S&P 500's 12.29% change.
According to market data, Janux Therapeutics, Inc. (JANX) stock's recent performance metrics show that over the last month, JANX is -59.52%, with a Year-to-Date (YTD) performance of -74.22%. Over the past year, the stock has seen a -75.42% change. These figures summarize JANX's price movements across various periods, reflecting its historical returns.
According to current financial data, JANX stock's P/E (TTM) ratio is -8.33, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for JANX, including P/S (552.96), P/B (0.87), and P/FCF (-11.52), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.